Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Merestinib + Ramucirumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Merestinib||LY2801653|LY-2801653||AXL Inhibitor 27 DDR1 Inhibitor 8 DDR2 inhibitor 7 FLT3 Inhibitor 55 MET Inhibitor 51 RON Inhibitor 10 ROS1 Inhibitor 14 Trk Receptor Inhibitor (Pan) 23 TYRO3 Inhibitor 8||Merestinib (LY2801653) inhibits several receptor tyrosine kinases including MET, MST1R (RON), AXL, MERTK, TYRO3, ROS1 fusions, PDGFRA, FLT3, TEK, DDR1/2, MKNK1/2, and NTRK1/2/3 with greatest activity against NTRK1, and may result in decreased tumor growth (PMID: 23275061, PMID: 24305878, PMID: 29568395, PMID: 32537847).|
|Ramucirumab||Cyramza||LY3009806||VEGFR2 Antibody 4||Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Merestinib + Ramucirumab||Phase I||Actionable||In a Phase I trial, the combination of Merestinib (LY2801653) and Cyramza (ramucirumab) demonstrated tolerability and resulted in a median overall survival of 8.9 months, median progression-free survival of 3.3 months, and stable disease in 52% (12/23) of patients with previously treated metastatic colorectal cancer (PMID: 32537847; NCT02745769).||32537847|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02745769||Phase I||Merestinib + Ramucirumab Abemaciclib + Ramucirumab||A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents||Completed||USA||2|